oral beclomethasone 17,21-dipropionate + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Gastrointestinal Graft vs Host Disease
Conditions
Acute Gastrointestinal Graft vs Host Disease
Trial Timeline
Oct 1, 2009 → May 1, 2012
NCT ID
NCT00926575About oral beclomethasone 17,21-dipropionate + Placebo
oral beclomethasone 17,21-dipropionate + Placebo is a phase 3 stage product being developed by Soligenix for Acute Gastrointestinal Graft vs Host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00926575. Target conditions include Acute Gastrointestinal Graft vs Host Disease.
What happened to similar drugs?
20 of 20 similar drugs in Acute Gastrointestinal Graft vs Host Disease were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00926575 | Phase 3 | Terminated |
Competing Products
20 competing products in Acute Gastrointestinal Graft vs Host Disease